SGRY

Surgery Partners Inc. (SGRY) | Rumor.io

Surgery Partners

SGRY

Attention (50-day avg)0%

Attention rank (50-day avg)#3,194

Bullish sentiment (50-day avg)100%

Price to earnings ratio3K

Market capitalization1.9B

Earnings per share-0.69

Dividend yield (TTM)—

Revenue (annual)3.3B

Net income (annual)98.9M

Social

What share of all stock conversation is about SGRY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Mar 4

Jefferies has issued a buy recommendation for $SGRY with a price target of $16.25.
Surgery Partners has acquired Preferred Vascular Group, expanding its surgical footprint, with Ziegler serving as exclusive advisor to the seller.
RBC Capital has maintained an Outperform rating on $SGRY, reaffirming its positive outlook on the stock.

Generated by AI

Sentiment

Of the messages about SGRY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100%	41.05% -37.03
Bearish	—	0%	0%	58.95% +37.03

Bullish· Jul 31

$SGRY is gaining, indicating a strong trend.
Accumulation is occurring, suggesting a potential increase in price.
$SGRY is a strong hold, implying confidence in the asset's value.

Bearish· Aug 9

KeyBanc downgraded $SGRY to sector weight, citing potential weakness in the sector.
Stifel downgraded $SGRY to sell with a $17 price target, citing weak Q2 results and soft guidance.
Surgery Partners, Inc. (SGRY) dropped 35% after an ugly Q2 and lowered guidance.

Generated by AI

Topics

Of the messages about SGRY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	50%	63.64%
Technical Analysis	—	0%	50%	8.06%
Analysts	—	0%	0%	21.69%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	1.86%
Macro	—	0%	0%	4.75%

Earnings· Nov 5

Surgery Partners, Inc. (SGRY) missed earnings per share (EPS) estimate by $0.10, but beat revenue expectations.
The company reported a net loss of $0.28 per share, which was better than the consensus estimate of a loss of $0.34 per share.
Surgery Partners reaffirmed its FY19 sales and adjusted EBITDA growth guidance, and reported Q3 revenue of $452.0M.

Announcements· Nov 21

Surgery Partners, Inc. ($SGRY) has priced an upsized $575 million public offering of common stock and a $225 million concurrent private placement to Bain Capital.
The company's shares are trading lower after the announcement, with a price drop of $2.25 (-8.24%) to $25.04.
The offering is part of Surgery Partners' efforts to raise capital, with the company planning to use the funds for general corporate purposes.

Generated by AI

Community

Of the messages about SGRY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	18.18%	9.09%	28.19%
Newcomers	—	81.82%	90.91%	71.81%

Regulars· Nov 10

Surgery Partners' special committee rejected a $25.75 per share offer, citing that it was too low and reaffirming the company's guidance.
The Chairman of Surgery Partners divested millions in equity, leading to a decline in the company's stock price and a subsequent downgrade of guidance.
Surgery Partners reported a decline in patient volumes and insurance payment trends, leading to a 14.2% drop in its stock price and a third quarter earnings miss, with adjusted EPS down 31.58% year-over-year.

Newcomers· Mar 3

New investors are taking note of SGRY's significant decline in stock price, with some experiencing losses after the company's Q4 earnings report and FY26 guidance fell short of expectations.
Focus is on SGRY's earnings report, where the company missed Q4 EPS by 60% and issued FY26 guidance below consensus, leading to a stock price drop of around 25% and a new 52-week low.
Despite facing challenges, SGRY is seen as having potential for recovery, with some investors holding onto the stock in anticipation of a potential rebound.

Generated by AI

News

Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know

Detailed price information for Zimmer Biomet Holdings (ZBH-N) from The Globe and Mail including charting and trades.

6d agoThe Globe and Mail

Surgery Partners (SGRY): Buy, Sell, or Hold Post Q2 Earnings?

Surgery Partners’s 30.8% return over the past six months has outpaced the S&P 500 by 12.8%, and its stock price has climbed to $15.67 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

6d agofinance.yahoo.com

Surgery Partners: A 'Buy' After Idaho Falls Asset Divestment (NASDAQ:SGRY)

7d agoSeeking Alpha

Surgery Partners (SGRY) Soars 15.7%: Is Further Upside Left in the Stock?

Surgery Partners (SGRY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

7d agoYahoo Finance

Analysts Offer Insights on Healthcare Companies: Surgery Partners (SGRY), Envista Holdings (NVST) and Inventiva (IVA)

Detailed price information for Surgery Partners CS (SGRY-Q) from The Globe and Mail including charting and trades.

11d agoThe Globe and Mail

Surgery Partners Lowers 2026 Revenue Guidance; Completes $797 Million Sale of Idaho Falls Facilities

Surgery Partners (SGRY) said Thursday it expects full-year 2026 revenue of $3.08 billion to $3.18 bi

12d agoYahoo Finance

Also Discussed

Investors talking about SGRY also mention

#	Name	Attention
1	Azenta, Inc.AZTA	0%0
2	Lyell Immunopharma, Inc.LYEL	0.01%new
3	Evolent Health IncEVH	0%0
4	CIVI - Civitas Resources, Inc.	——
5	SkyWest Inc.SKYW	0%new
6	Customers Bancorp Inc.CUBI	0%0
7	FOLD - Amicus Therapeutics, Inc.	——
8	Community Health Systems IncCYH	0%new
9	NICE Ltd. Sponsored ADRNICE	0%0
10	GeneDx Holdings Corp. Class A Common StockWGS	0%+0

Surgery Partners Inc.

Healthcare
Medical Care Facilities

Surgery Partners Inc. is a healthcare services company that owns and operates a broad network of surgical facilities and related care services across the United States. The company focuses on outpatient and short-stay procedures delivered through ambulatory surgery centers and surgical hospitals, serving patients in specialties such as orthopedics, pain management, ophthalmology, gastroenterology, and general surgery. Its integrated model also includes anesthesia services, multi-specialty physician practices, diagnostic testing, urgent care facilities, and other ancillary services that support clinical operations. Surgery Partners Inc. plays a significant role in the outpatient care market by connecting providers, facilities, and supporting services within a coordinated healthcare delivery platform. Headquartered in Brentwood, Tennessee, the company serves a wide range of communities through locations in multiple states.

Website

Location

340 Seven Springs Way

Brentwood, TN, 37027

United States

Social

What share of all stock conversation is about SGRY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Mar 4

Jefferies has issued a buy recommendation for $SGRY with a price target of $16.25.
Surgery Partners has acquired Preferred Vascular Group, expanding its surgical footprint, with Ziegler serving as exclusive advisor to the seller.
RBC Capital has maintained an Outperform rating on $SGRY, reaffirming its positive outlook on the stock.

Generated by AI

Sentiment

Of the messages about SGRY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100%	41.05% -37.03
Bearish	—	0%	0%	58.95% +37.03

Bullish· Jul 31

$SGRY is gaining, indicating a strong trend.
Accumulation is occurring, suggesting a potential increase in price.
$SGRY is a strong hold, implying confidence in the asset's value.

Bearish· Aug 9

KeyBanc downgraded $SGRY to sector weight, citing potential weakness in the sector.
Stifel downgraded $SGRY to sell with a $17 price target, citing weak Q2 results and soft guidance.
Surgery Partners, Inc. (SGRY) dropped 35% after an ugly Q2 and lowered guidance.

Generated by AI

Topics

Of the messages about SGRY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	50%	63.64%
Technical Analysis	—	0%	50%	8.06%
Analysts	—	0%	0%	21.69%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	1.86%
Macro	—	0%	0%	4.75%

Earnings· Nov 5

Surgery Partners, Inc. (SGRY) missed earnings per share (EPS) estimate by $0.10, but beat revenue expectations.
The company reported a net loss of $0.28 per share, which was better than the consensus estimate of a loss of $0.34 per share.
Surgery Partners reaffirmed its FY19 sales and adjusted EBITDA growth guidance, and reported Q3 revenue of $452.0M.

Announcements· Nov 21

Surgery Partners, Inc. ($SGRY) has priced an upsized $575 million public offering of common stock and a $225 million concurrent private placement to Bain Capital.
The company's shares are trading lower after the announcement, with a price drop of $2.25 (-8.24%) to $25.04.
The offering is part of Surgery Partners' efforts to raise capital, with the company planning to use the funds for general corporate purposes.

Generated by AI

Community

Of the messages about SGRY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	18.18%	9.09%	28.19%
Newcomers	—	81.82%	90.91%	71.81%

Regulars· Nov 10

Surgery Partners' special committee rejected a $25.75 per share offer, citing that it was too low and reaffirming the company's guidance.
The Chairman of Surgery Partners divested millions in equity, leading to a decline in the company's stock price and a subsequent downgrade of guidance.
Surgery Partners reported a decline in patient volumes and insurance payment trends, leading to a 14.2% drop in its stock price and a third quarter earnings miss, with adjusted EPS down 31.58% year-over-year.

Newcomers· Mar 3

New investors are taking note of SGRY's significant decline in stock price, with some experiencing losses after the company's Q4 earnings report and FY26 guidance fell short of expectations.
Focus is on SGRY's earnings report, where the company missed Q4 EPS by 60% and issued FY26 guidance below consensus, leading to a stock price drop of around 25% and a new 52-week low.
Despite facing challenges, SGRY is seen as having potential for recovery, with some investors holding onto the stock in anticipation of a potential rebound.

Generated by AI

Surgery Partners

Social

Mar 4

Bullish· Jul 31

Bearish· Aug 9

Earnings· Nov 5

Announcements· Nov 21

Regulars· Nov 10

Newcomers· Mar 3

Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know

Surgery Partners (SGRY): Buy, Sell, or Hold Post Q2 Earnings?

Surgery Partners: A 'Buy' After Idaho Falls Asset Divestment (NASDAQ:SGRY)

Surgery Partners (SGRY) Soars 15.7%: Is Further Upside Left in the Stock?

Analysts Offer Insights on Healthcare Companies: Surgery Partners (SGRY), Envista Holdings (NVST) and Inventiva (IVA)

Surgery Partners Lowers 2026 Revenue Guidance; Completes $797 Million Sale of Idaho Falls Facilities

Also Discussed

Surgery Partners Inc.

Company Information

Location

Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know

Surgery Partners (SGRY): Buy, Sell, or Hold Post Q2 Earnings?

Surgery Partners: A 'Buy' After Idaho Falls Asset Divestment (NASDAQ:SGRY)

Surgery Partners (SGRY) Soars 15.7%: Is Further Upside Left in the Stock?

Analysts Offer Insights on Healthcare Companies: Surgery Partners (SGRY), Envista Holdings (NVST) and Inventiva (IVA)

Surgery Partners Lowers 2026 Revenue Guidance; Completes $797 Million Sale of Idaho Falls Facilities

Also Discussed

Social

Mar 4

Bullish· Jul 31

Bearish· Aug 9

Earnings· Nov 5

Announcements· Nov 21

Regulars· Nov 10

Newcomers· Mar 3